Live, Attenuated Rubella-Virus Vaccine

Publisher Website
Google Scholar
Abstract
HIGH priority is being given in the United States and Europe to the development of an effective live, attenuated rubella (German-measles) virus vaccine. To be acceptable, a rubella vaccine should cause little if any clinical reaction, should induce lasting immunity in essentially all recipients, should be noncontagious to susceptible contacts, especially pregnant women, and should be prepared with the use of a safe and acceptable cell culture.First studies by our group1 of a highly purified and concentrated killed rubella-virus vaccine showed development in children of heat-labile (56°C) neutralizing antibodies that were not protective on challenge with live virus. Reports . . .